Five New EU Filings Leave Starting Blocks at EMA
Fast-Track Rejection For Amivantamab And Voxelotor
There is one orphan drug among the five new marketing authorization applications that the European Medicines Agency has under review. All five drugs will be reviewed under standard review timelines.
You may also be interested in...
New medicines under evaluation at the European Medicines Agency.
Novo Nordisk’s newer GLP1 products for diabetes, Ozempic and Rybelsus, drove the company’s sales growth in 2020, and with its CSO retiring after a two-decade shift, internal appointments are made to lead a reorganized R&D function.
Without Otezla’s $2.2bn in 2020 sales, Amgen’s full-year revenue would have been slightly lower than in 2019, which is why all eyes are on the company’s R&D programs and near-term approvals.